Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Leukemia|October 18, 2012
Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reducedA Shimoni, N Shem-Tov, A Chetrit, et al.
Bone Marrow Transplantation|March 30, 2001
Engraftment-associated hypophosphatemia--the role of cytokine release and steep leukocyte rise post stem cell transplantationP Raanani, I Levi, F Holzman, et al.
Leukemia|February 20, 2003
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemiasA Shimoni, N Kröger, A R Zander, et al.
Bone Marrow Transplantation|November 21, 2007
Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphomaA Shimoni, S T Zwas, Y Oksman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphomaA Avigdor, S Bulvik, I Levi, et al.
Leukemia Research|August 24, 1999
Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabineP Raanani, O Shpilberg, S Gillis, et al.
Leukemia|November 5, 2004
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioningA Shimoni, N Kröger, T Zabelina, et al.
Leukemia|July 30, 2002
Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysisA Shimoni, A Nagler, C Kaplinsky, et al.
Leukemia|October 14, 2006
Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cellsH Gal, N Amariglio, L Trakhtenbrot, et al.
Bone Marrow Transplantation|May 17, 2016
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantationP Tsirigotis, I Danylesko, K Gkirkas, et al.
Pageof 3